Projects per year
Personal profile
Biography
Dr Andrew Wei is a Victorian Cancer Agency Research Fellow and Haematologist at the Alfred Hospital. Andrew conducts clinical and translational AML research through dual appointments at the Alfred Hospital and Monash University.
After completing doctoral studies at the Walter and Eliza Hall Institute of Medical Research in 2005, he joined the Alfred Hospital in 2008 to develop the AML research program. He has been the AML disease group chairperson for Australasian Leukaemia and Lymphoma Group since 2009 and has led multiple nationwide cooperative group studies as chief investigator. His doctoral research studies contributed to discoveries elucidating the functional interaction between Bcl-2 family members (Molecular Cell 2005;17(3):393-403), the role of Mcl-1 in cancer susceptibility to ABT-737 (Cancer Cell. 2006;10(5):389-99) and the pro-survival function of the EBV Bcl-2 homologue BHRF-1 (PLoS Pathogens 2010;6[12]).
Dr Wei is an executive member of the ALLG Scientific Advisory Committee, a member of the National Medical and Scientific Advisory Committee of the Leukaemia Foundation of Australia and Head of Leukaemia Research at the Alfred hospital. He sits on the International Steering Committee for Celgene providing expert advice on AML. To enhance translational research, Dr Wei has established the Alfred Haematology Tissue Bank, the diagnostic molecular haematology laboratory and a pre-clinical research laboratory to focus on the role of targeting survival pathways in AML.
Related Links:
- Australian Centre For Blood Diseases, Leukaemia Research Group Leader http://www.acbd.monash.org/research/leukaemia-tr-group.html
- Professional Profile www.acbd.monash.org/staff/wei.html
Research interests
Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.
Projects:
- Targetting 'survival kinases' in leukemic stem and progenitor cells
- The role of inositol phosphatases in regulating normal and malignant hemopoiesis
- Human models of AML
Monash teaching commitment
2007 - Present : Adjunct senior lecturer
Clinical activities
Investigator initiated AML trail funding:
- Phase 1 study of RAD001 and low dose ara-C for elderly AML
- Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
- Phase 1 study of azacitidine and everolimus in relapsed AML
- Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
- Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML
- Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML
Cooperative Group Studies Local Site PI:
- Phase 3 study: ALLG AML M12 study
- Phase 2 study: ALLG APML M4 study
- Phase 2/3: UK MRC16 AML study
Company sponsored studies as local site PI:
- Phase 2 study: CEP-701 in relapsed AML
- Phase 2 study: AS1411 in relapsed AML
- Phase 2 study: Midostaurin in systemic mastocytosis
- Phase 2/3 study: AZD1152 in older AML
- Phase 3 study: PKC412 in AML
- Phase 3 study: Amonafide in secondary AML
- Phase 3 study: Elacytarabine in relapsed AML
- Phase 3: Voreloxin in relapsed AML
- Phase 1: KB004 in advanced haematological malignancies
- Phase 1: Meisoindigo in AML unfit for chemotherapy
Keywords
- Acute myeloid leukaemia
- Azacytidine
- BH3
- Bcl-2
- Lenalidomide
- Leukaemia Foundation
- Leukemia
- Lymphoma
- Mcl-1
- Relapse and refractory
- Research Fellow
- Victorian Cancer Agency
- clinical AML
- leukaemic stem cells
- translational AML
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2009 2022
The PRECISE assay: Personalised medicine for cancer patients using next-generation sequencing
To, S. Q. G., Azad, A., Shortt, J., Wei, A., Shackleton, M. & Kenealy, M.
1/12/17 → 1/12/20
Project: Research
The International Acute Myeloid Leukaemia Platform Consortium (IAPC)
Wei, A., Roberts, A., Dawson, M. A., Reynolds, J., Ritchie, D., Ekert, P. G. & Ivey, A.
13/04/17 → 12/04/20
Project: Research
Establishing a Monash Partners national reference centre for molecular monitoring of residual disease (MRD) in acute myeloid leukaemia
Wei, A., Ivey, A., Fleming, S. A., Tiong, I. S., McManus, J. & Ting, S. B. N.
1/01/17 → 31/12/19
Project: Research
Toward effective targeted therapies for Acute Myeloid Leukaemia (AML)
Wei, A., Bohlander, S. & Herold, M. J.
1/01/17 → 31/12/19
Project: Research
Research Output 2008 2018
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Tiong, I. S., Reynolds, J., Bradstock, K. F., Seymour, J. F., Wei, A. H. & on behalf of the Australasian Leukaemia & Lymphoma Group 22 Aug 2018 In : Blood Cancer Journal. 8, 9, 5 p., 84Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Teh, T. C., Nguyen, N. Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A., Cummins, K., Lackovic, K., Blombery, P., Thompson, E., Ekert, P. G., Lessene, G., Glaser, S. P., Huang, D. C. S., Roberts, A. W., Guthridge, M. A. & Wei, A. H. 1 Feb 2018 In : Leukemia. 32, 2, p. 303-312 10 p.Research output: Contribution to journal › Article › Research › peer-review
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
Tiong, I. S., Tan, P., McManus, J., Cummings, N., Sadawarte, S., Catalano, J., Hills, R. & Wei, A. 2018 In : Leukemia and Lymphoma. 59, 2, p. 493-496 4 p.Research output: Contribution to journal › Letter › Research › peer-review
Accelerating Early Drug Development: Come on Down Under
Wei, A. Jul 2017 In : Annals of Oncology. 28, 7, p. 1655-1657 3 p., mdx101Research output: Contribution to journal › Article › Other › peer-review
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
Kantarjian, H. M. , Stein, A. , Gökbuget, N. , Fielding, A. K. , Schuh, A. C. , Ribera, J. M. , Wei, A. , Dombret, H. , Foà, R. , Bassan, R. , Arslan, Ö. , Sanz, M. A. , Bergeron, J. , Demirkan, F. , Lech-Maranda, E. , Rambaldi, A. , Thomas, X. , Horst, H-A. , Brüggemann, M. , Klapper, W. & 6 others 2 Mar 2017 In : New England Journal of Medicine. 376, 9, p. 836-847 12 p.Research output: Contribution to journal › Article › Research › peer-review
Prizes
2003: Albert Baikie Award, Best Oral Abstract Presentation, Haematology Society of Australia
Andrew Wei (Recipient), 2004
Prize: Prize (including medals and awards)
2003: Young Investigator Award, Best Oral Abstract Presentation, Annual Scientific Meeting, Hobart
Andrew Wei (Recipient), 2003
Prize: Prize (including medals and awards)
2004: New Investigator Award, Best Oral Abstract, Annual Scientific Meeting, Canberra
Andrew Wei (Recipient), 2004
Prize: Prize (including medals and awards)
Activities 2012 2012
- 8 Membership of an advisory panel/policy group/ board
HAEMATOLOGY SOCIETY OF AUSTRALIA AND NEW ZEALAND (External organisation)
Wei, A. (Member)1 Jan 2012
Activity: Membership of an advisory panel/policy group/ board
The Royal Australasian College of Physicians (External organisation)
Wei, A. (Member)1 Jan 2012
Activity: Membership of an advisory panel/policy group/ board
AMERICAN SOCIETY OF HAEMATOLOGY (External organisation)
Wei, A. (Member)1 Jan 2012
Activity: Membership of an advisory panel/policy group/ board
EUROPEAN HAEMATOLOGY ASSOCIATION (External organisation)
Wei, A. (Member)1 Jan 2012
Activity: Membership of an advisory panel/policy group/ board
Royal College of Pathologists of Australasia (External organisation)
Wei, A. (Member)1 Jan 2012
Activity: Membership of an advisory panel/policy group/ board